BioVie Phase 2 SUNRISE-PD trial of bezisterim shows statistically significant improvements vs placebo

BIOVIE INC.

Statistically significant improvements on MDS-UPDRS Parts I, II, III and composite EPNIC-15 (p=0.0006).
Bezisterim improved biomarkers of neuroinflammation and systemic inflammation; composite neuroinflammation measure p=0.0018.
283 of 380 proteins shifted toward lower inflammatory burden (binomial p=3.2e-22).
Bezisterim well-tolerated; adverse events 39.3% vs 51.7% placebo, no severe/serious AEs.
Conference call scheduled for Aug 12, 2026 to discuss results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.